Key result
Atorvastatin /day reduced total cholesterol by 23% at 36 months in severe CKD patients, though 21% discontinued therapy due to adverse effects.
Why the study?
Does atorvastatin 10 mg/day improve lipid profiles in patients with severe chronic kidney disease (stages 4 and 5)?
RCT (n=143)
Open-label
randomized
Does atorvastatin 10 mg/day improve lipid profiles in patients with severe chronic kidney disease (stages 4 and 5)?
Atorvastatin 10 mg/day effectively lowers LDL cholesterol in severe CKD patients, but is associated with a 21% discontinuation rate due to side effects like gastrointestinal discomfort and headache.
Answers are grounded in this paper and cite their sources.
Demonstrates lipid-lowering efficacy in severe CKD but requires close monitoring for tolerability.
OBJECTIVE: To investigate the efficacy and safety of a daily dose of 10 mg of atorvastatin in patients with chronic kidney disease (CKD) stages 4 and 5 and a glomerular filtration rate of <30 ml/min. MATERIAL AND METHODS: This was an open, prospective, randomized study. A total of 143 patients were included: 73 were controls and 70 were prescribed 10 mg/day of atorvastatin. As efficacy variables, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride levels were determined at the start of the study and at 1, 3, 6, 12, 18, 24, 30 and 36 months. RESULTS: The follow-up period was a mean of 20+/-14.4 months (range 1-36 months) for those on atorvastatin versus 22+/-12.7 months (range 0.5-36 months) for the controls. Compared with baseline values, patients treated with atorvastatin had significantly lower concentrations of total cholesterol at Month 36 (5.8 vs 4.4 mmol/l; -23%; p<0.001), of LDL cholesterol at Month 36 (3.6 vs 2.2 mmol/l; -35%; p<0.001) and of triglycerides at Months 24 (2.5 vs 1.9 mmol/l) and 36 (2.5 vs 1.8 mmol/l). The controls had significantly reduced levels of total cholesterol at Month 36 (p<0.21) and of LDL cholesterol at Months 30 and 36. Compared with the controls, the atorvastatin group had lower levels of total cholesterol and LDL cholesterol at Months 1-30. Fifteen patients (21%) stopped taking their medication as they could not tolerate the side-effects, the most frequent complaints being gastrointestinal discomfort and headache. CONCLUSION: Although the medication caused no severe adverse events, we recommend caution when using atorvastatin for severe CKD patients until further evidence of its safety and efficacy is verified.
No takes yet. Share an insight, caveat, or question.
Holmberg et al. (2005) conducted an RCT in chronic kidney disease (CKD) stages 4 and 5 (n=143). Atorvastatin vs. Control was evaluated on Total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels (-23% reduction in total cholesterol vs baseline, p=<0.001). Atorvastatin /day reduced total cholesterol by 23% at 36 months in severe CKD patients, though 21% discontinued therapy due to adverse effects.
Synapse has enriched 10 related papers. Consider them for comparative context: